FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382011505> ?p ?o ?g. }

• W4382011505 endingPage "829" @default.
• W4382011505 startingPage "823" @default.
• W4382011505 abstract "To compare the efficacy of eltrombopag combined with cyclosporine A (CsA) and CsA alone in patients with transfusion-dependent non-severe aplastic anemia (TD-NSAA).The clinical data of 76 patients with treatment-naive TD-NSAA in Ningde Municipal Hospital of Ningde Normal University and Affiliated Hospital of Nantong University from December 2017 to June 2021 were retrospectively analyzed. Among them, 45 cases were treated with eltrombopag combined with CsA, and 31 patients with compatible baseline characters were treated with CsA alone. The efficacy of patients between the two groups was compared, and the factors affecting the curative effects were also analyzed.There were significant differences in hematological response (HR) and complete response(CR) rates between the two groups at 3, 6, 12 months, and follow-up endpoint of treatment (P<0.05). With the prolongation of eltrombopag treatment time, the curative effect increased gradually, and the patients achieved more CR and HR rates by the end of the follow-up period. Simultaneously, with the increase in the maximum stable dose of eltrombopag, the HR rate increased gradually. The megakaryocyte count in eltrombopag group was higher than that in control at 6 and 12 months (P<0.05). Compared with the control group, the median time of platelet transfusion independence in eltrombopag group was more shorter (P=0.018), and the median platelets transfusion volume was lower (P=0.009). At 3, 6, 12 months after eltrombopag, the change of platelet in eltrombopag group was higher than that in the control group (P<0.05). Analysis of related factors affecting the efficacy showed that sex, age, iron overload, platelet count before treatment had no effect on the efficacy, and the median maximum stable dosage and the administration period for eltrombopag were related to the curative effect. The patients of eltrombopag group experienced adverse events of varying degrees, but the reactions were mild and mostly tolerated.Eltrombopag can effectively improve the hematopoietic response and promote platelet recovery for TD-NSAA patients with relatively more residual hematopoietic cells, and it is safe and well tolerated.艾曲泊帕对输血依赖的非重型再生障碍性贫血免疫抑制治疗疗效的影响.比较艾曲泊帕联合环孢素(CsA)和单用CsA治疗输血依赖的非重型再生障碍性贫血(TD-NSAA)的疗效.回顾性分析2017年12月至2021年6月宁德师范学院附属宁德市医院及南通大学附属医院治疗中心76例初治TD-NSAA的临床资料，其中45例使用艾曲泊帕联合CsA治疗(艾曲泊帕治疗组)，31例为同期基线匹配单用CsA治疗患者（对照组），比较两组患者疗效，并分析影响疗效的相关因素.两组在治疗3、6、12个月及随访终点时血液学反应(HR)及完全缓解(CR)均存在明显统计学差异(P<0.05)，随着艾曲泊帕治疗时间的延长疗效进一步提高，至随访终点，获得更多的CR及HR，同时随着艾曲泊帕最大稳定剂量的增加，HR有逐渐增加趋势。治疗6、12个月，艾曲泊帕治疗组骨髓巨核细胞数均明显高于对照组(P<0.05)，其脱离血小板输注中位时间较对照组短(P=0.018)，且中位血小板输注量也明显低于对照组(P=0.009)。艾曲泊帕治疗组在3、6、12个月血小板较基线升高值均高于对照组(P<0.05)。影响疗效的相关因素分析显示，患者性别、年龄、铁超负荷及治疗前血小板数量与疗效无相关性，而艾曲泊帕的中位稳定治疗剂量和中位治疗时间与疗效存在相关性。艾曲泊帕治疗组中部分患者有不同程度的不良反应，但反应轻微，多可耐受.对于残存造血细胞较多的TD-NSAA患者，加用艾曲泊帕可明显改善HR，加快血小板的恢复，安全性及耐受性良好." @default.
• W4382011505 created "2023-06-27" @default.
• W4382011505 creator A5003483109 @default.
• W4382011505 creator A5014708668 @default.
• W4382011505 creator A5029048630 @default.
• W4382011505 creator A5058022843 @default.
• W4382011505 creator A5077943592 @default.
• W4382011505 date "2023-06-01" @default.
• W4382011505 modified "2023-09-24" @default.
• W4382011505 title "[Effect of Eltrombopag on Response to Immunosuppressive Therapy in Patients with Transfusion-Dependent Non-Severe Aplastic Anemia]." @default.
• W4382011505 doi "https://doi.org/10.19746/j.cnki.issn.1009-2137.2023.03.030" @default.
• W4382011505 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37356946" @default.
• W4382011505 hasPublicationYear "2023" @default.
• W4382011505 type Work @default.
• W4382011505 citedByCount "0" @default.
• W4382011505 crossrefType "journal-article" @default.
• W4382011505 hasAuthorship W4382011505A5003483109 @default.
• W4382011505 hasAuthorship W4382011505A5014708668 @default.
• W4382011505 hasAuthorship W4382011505A5029048630 @default.
• W4382011505 hasAuthorship W4382011505A5058022843 @default.
• W4382011505 hasAuthorship W4382011505A5077943592 @default.
• W4382011505 hasConcept C126322002 @default.
• W4382011505 hasConcept C141071460 @default.
• W4382011505 hasConcept C168563851 @default.
• W4382011505 hasConcept C203092338 @default.
• W4382011505 hasConcept C2776689292 @default.
• W4382011505 hasConcept C2778248108 @default.
• W4382011505 hasConcept C2780007613 @default.
• W4382011505 hasConcept C2780588981 @default.
• W4382011505 hasConcept C2781440808 @default.
• W4382011505 hasConcept C2993327898 @default.
• W4382011505 hasConcept C71924100 @default.
• W4382011505 hasConcept C89560881 @default.
• W4382011505 hasConcept C90924648 @default.
• W4382011505 hasConceptScore W4382011505C126322002 @default.
• W4382011505 hasConceptScore W4382011505C141071460 @default.
• W4382011505 hasConceptScore W4382011505C168563851 @default.
• W4382011505 hasConceptScore W4382011505C203092338 @default.
• W4382011505 hasConceptScore W4382011505C2776689292 @default.
• W4382011505 hasConceptScore W4382011505C2778248108 @default.
• W4382011505 hasConceptScore W4382011505C2780007613 @default.
• W4382011505 hasConceptScore W4382011505C2780588981 @default.
• W4382011505 hasConceptScore W4382011505C2781440808 @default.
• W4382011505 hasConceptScore W4382011505C2993327898 @default.
• W4382011505 hasConceptScore W4382011505C71924100 @default.
• W4382011505 hasConceptScore W4382011505C89560881 @default.
• W4382011505 hasConceptScore W4382011505C90924648 @default.
• W4382011505 hasIssue "3" @default.
• W4382011505 hasLocation W43820115051 @default.
• W4382011505 hasOpenAccess W4382011505 @default.
• W4382011505 hasPrimaryLocation W43820115051 @default.
• W4382011505 hasRelatedWork W1985782567 @default.
• W4382011505 hasRelatedWork W2031847788 @default.
• W4382011505 hasRelatedWork W2154749124 @default.
• W4382011505 hasRelatedWork W2330900356 @default.
• W4382011505 hasRelatedWork W2384490600 @default.
• W4382011505 hasRelatedWork W2732316317 @default.
• W4382011505 hasRelatedWork W2791686711 @default.
• W4382011505 hasRelatedWork W3031484087 @default.
• W4382011505 hasRelatedWork W3046168531 @default.
• W4382011505 hasRelatedWork W4306253774 @default.
• W4382011505 hasVolume "31" @default.
• W4382011505 isParatext "false" @default.
• W4382011505 isRetracted "false" @default.
• W4382011505 workType "article" @default.